Gauss

Eutda cytotoxicity assay kit containing: 960 Tests

Réf. UGAP : 3731285 Réf. Fournisseur : AD0116 Réf. Constructeur : AD0116
Eutda cytotoxicity assay kit containing: 960 Tests
Franco de port et d'emballage pour toutes les commandes supérieures à 80€ HT.

Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
La quantité choisie doit être comprise entre 1 et 999 999.
Il ne reste que 0 exemplaires.

Points clés

Permet d'améliorer la sensibilité et la gamme dynamique de votre ELISA en changeant uniquement le mode de détection avec un système de fluorescence très stable.

DELFIA time-resolved fluorescence cell cytotoxicity assays offer a non-radioactive method to Chromium 51, for use in cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity (ADCC) studies. The method is based on loading cells with an acetoxymethyl ester of a fluorescence enhancing ligand. After the ligand has penetrated the cell membrane the ester bonds are hydrolyzed within the cell to form a hydrophilic ligand, which no longer passes through the membrane. After cytolysis the released ligand is introduced to a europium solution to form a fluorescent chelate. The measured signal correlates directly with the amount of lysed cells. Reagents for the assay are also available separately: Lysis buffer (30 mL), #4005-0010 DELFIA Eu-Solution (200 mL), #C135-100 DELFIA BATDA labeling reagent (50 µL), #C136-100 Selected references: Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. PNAS 103, 4005–4010 (2006). Tsai, C.-Y. et al. Type I IFNs and IL-18 Regulate the Antiviral Response of Primary Human γδ T Cells against Dendritic Cells Infected with Dengue Virus. The Journal of Immunology 194, 3890–3900 (2015). Mehta, R. S., Chen, X., Antony, J., Boyiadzis, M. & Szabolcs, P. Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts. J Immunother 39, 71–80 (2016). Snyder, K. M. et al. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells. Front Immunol 9, (2018). Yu, T., Qiao, C., Lv, M. & Tang, L. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity. BMC Biotechnology 19, 28 (2019).

En savoir plus

Garantie

Garantie 0 Mois

Description

Permet d'améliorer la sensibilité et la gamme dynamique de votre ELISA en changeant uniquement le mode de détection avec un système de fluorescence très stable.

DELFIA time-resolved fluorescence cell cytotoxicity assays offer a non-radioactive method to Chromium 51, for use in cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity (ADCC) studies. The method is based on loading cells with an acetoxymethyl ester of a fluorescence enhancing ligand. After the ligand has penetrated the cell membrane the ester bonds are hydrolyzed within the cell to form a hydrophilic ligand, which no longer passes through the membrane. After cytolysis the released ligand is introduced to a europium solution to form a fluorescent chelate. The measured signal correlates directly with the amount of lysed cells. Reagents for the assay are also available separately: Lysis buffer (30 mL), #4005-0010 DELFIA Eu-Solution (200 mL), #C135-100 DELFIA BATDA labeling reagent (50 µL), #C136-100 Selected references: Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. PNAS 103, 4005–4010 (2006). Tsai, C.-Y. et al. Type I IFNs and IL-18 Regulate the Antiviral Response of Primary Human γδ T Cells against Dendritic Cells Infected with Dengue Virus. The Journal of Immunology 194, 3890–3900 (2015). Mehta, R. S., Chen, X., Antony, J., Boyiadzis, M. & Szabolcs, P. Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts. J Immunother 39, 71–80 (2016). Snyder, K. M. et al. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells. Front Immunol 9, (2018). Yu, T., Qiao, C., Lv, M. & Tang, L. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity. BMC Biotechnology 19, 28 (2019).

Caractéristiques

Marque
REVVITY
Libellé produit fabricant
DELFIA® EuTDA Cytotoxicity Reagents
Référence distributeur
AD0116
Référence fabricant
AD0116
Fournisseur
REVVITY
Reprise en cas d’erreur client
non
Lieu de fabrication
États-Unis
Lieu de stockage
Pays-Bas
Domaine de recherche
biologie cellulaire
Délai de péremption à la date de livraison
6 mois
Soumis à carboglace
oui
Soumis à réglementation
non
Température de conservation (°C)
+2 à +8 °C
Type d’application
viabilité cellulaire
Vendu par
960 tests
Quantité
N/A
Nomenclature Nacres
NA.84
Nomenclature CEA
SGP01
Nomenclature IRSN
273
Nomenclature INSERM
NA.NA84
Nomenclature CNRS
NA84
Nomenclature CHU
18.551
Nomenclature DGOS
LD11AOOO
Type d'échantillon
sérum, plasma, surnageant de culture cellulaire, tissu
Certification
RUO

Fournisseur